ArticleExperimental dermatology2025
Enhancing Early Detection of Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Integrating AI With Histopathological Assessments.
Article in Experimental dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- AI-Based Segmentation of Wound Types Caused by Epidermolysis Bullosa.Experimental dermatology · 2026Article
- A scoping review of human-AI collaboration patterns and task divisions in healthcare applications.NPJ digital medicine · 2026Article
- Enhancing Early Detection of Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Integrating AI With Histopathological Assessments.Experimental dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cutaneous squamous cell carcinoma (CSCC) patients at high risk for metastasis are insufficiently identified with current staging systems. Advances in digital pathology and artificial intelligence (AI) might assist by extracting detailed and reproducible predictive features from haematoxylin and eosin slides. We evaluated a multi-step convolutional neural network (CNN) as an assistive tool to provide detailed complementary histopathological variables towards identifying high-risk CSCC. Using a nested case-control design, we studied patients diagnosed with primary CSCC in the Netherlands from 2007 to 2018, with metastatic patients as cases and non-metastatic patients as controls. The dataset was divided into a development set (130 patients) and an evaluation set (244 patients). Four elaborative variables were derived from a CNN model for object detection and semantic segmentation, complementing six dermatopathologist-scored histopathological variables. Dermatopathologists involved were blinded to the outcomes. We assessed the efficacy of these variables using multivariable logistic regression (MR) models and odds ratios (OR) for metastatic CSCC on the evaluation set. The MR model fitting was assessed using the pairwise concordance index (C-index). The combined dermatopathologist-AI model yielded the highest C-index (0.92 [0.87-0.95]). Significant variables in the combined model included model-derived tumour area (OR 1.35 [1.00-1.84]) which complemented scored tumour diameter (OR 1.54 [0.75-3.17]) and model-derived nuclei density (OR 3.14 [1.08-9.17]) as a counterpart of scored tumour differentiation grades (OR 10.6 [3.01-37.0] and 11.5 [2.95-44.5]). The CNN model can derive detailed and reproducible histopathological variables associated with metastatic risk in CSCC, complementing the current pathologist-based assessment and enhancing the identification of high-risk CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.